Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587478 · ClinicalTrials.gov registry record · Phase 1
A Study of EDP-323 in Healthy Subjects
A Phase 1 study of RSV Infection, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 1
- Study location
NCT05587478 is a Phase 1 study of RSV Infection that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 82 participants, below the 737-participant average among 8 other RSV Infection trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05587478, a Phase 1 study of RSV Infection, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EDP-323
Study Locations (1)
Kansas
- ICON, plc. - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2022-09-29 |
| Est. Completion | 2023-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05587478
The ClinicalTrials.gov registry entry for NCT05587478 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 737-participant average among 8 other RSV Infection trials with a reported enrollment target (89% lower). The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with RSV Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05587478 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT05587478 about?
NCT05587478 is a clinical study titled "A Study of EDP-323 in Healthy Subjects". This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.
What is the current status of trial NCT05587478?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2022-09-29. Estimated completion is 2023-03-29.
What conditions does trial NCT05587478 study?
This clinical trial studies the following conditions: RSV Infection.
What interventions are being tested in trial NCT05587478?
The interventions under investigation include: Placebo (DRUG), EDP-323 (DRUG).
Who is sponsoring clinical trial NCT05587478?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05587478 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
RECRUITING · Phase 1
-
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
COMPLETED · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.